

Media Release

15 November 2018

**SENIOR RESEARCH EXECUTIVES FROM BOEHRINGER INGELHEIM AND
THE GARVAN INSTITUTE TO PRESENT AT PHARMAXIS INVESTOR
RESEARCH BRIEFING**

Pharmaceutical research company Pharmaxis (ASX: PXS) advises that it will host an investor research briefing on Tuesday, 20 November from 10am to 12.00pm (AEDT) that will feature presentations by a Boehringer Ingelheim global project manager and a research leader from the Garvan Institute of Medical Research. The event will also provide an overview of the Pharmaxis drug discovery pipeline including the anti-inflammatory drug currently being developed by Boehringer Ingelheim, work in collaboration with the Garvan Institute of Medical Research on an anti-fibrotic LOX inhibitor targeting pancreatic cancer and the anti-fibrotic LOXL2 inhibitor program currently completing phase 1 trials and extended toxicity studies.

This is a unique opportunity to hear directly from the Pharmaxis executive research team along with the perspectives of a committed pharmaceutical partner and a leading medical research institute.

Attendance at this event is by invitation only. A live webcast will be accessible to all investors via the homepage of the Pharmaxis website at www.pharmaxis.com.au and will be available for replay after the event.

#ends#

SOURCE: Pharmaxis Ltd, Sydney, Australia

CONTACT:

Media: Felicity Moffatt: T +61 418 677 701, E felicity.moffatt@pharmaxis.com.au

Investor relations: David McGarvey: T +61 438 880 106, E david.mcgarvey@pharmaxis.com.au

About Pharmaxis

Pharmaxis (ACN 082 811 630) is an Australian pharmaceutical research company focused on inflammation and fibrosis with a portfolio of products at various stages of development and approval. Its product Bronchitol® for cystic fibrosis is marketed in Europe, Russia and Australia. Its product Aridol® for the assessment of asthma is sold in Europe, Australia and Asia. The company's development pipeline is centred on its expertise in amine oxidase chemistry and includes a series of Lysyl Oxidase Inhibitors under clinical development targeting fibrotic diseases of the heart, kidney, liver and lung. In May 2015, Boehringer Ingelheim acquired the Pharmaxis investigational drug PXS-4728A, a potent inhibitor of Semicarbazide-Sensitive Amine Oxidase (SSAO), to develop it for the treatment of the liver-related condition Non-alcoholic Steatohepatitis (NASH) and other inflammatory diseases. Pharmaxis is listed on the Australian Securities Exchange (symbol PXS). The company's head office, manufacturing and research facilities are located in Sydney, Australia. For more information about Pharmaxis, please see www.pharmaxis.com.au

Forward-Looking Statements

Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential of products and drug candidates. All forward-looking statements included in this media release are based upon information available to us as of the date hereof. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. These forward-looking statements are not guarantees or predictions of future results, levels of performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this document. Except as required by law we undertake no obligation to update these forward-looking statements as a result of new information, future events or otherwise.